Admittedly, part of the reason we are so drawn to Nexus, is because of the similarities they bear to us: Namely, we are both active in a sort of Oligopoly consisting of large and inflexible competitors, who stick to conventional methods of the past. In reality though, it is only with an out-of-the-box approach that we can find newer and simpler solutions which disrupt existing infrastructures.
When we first took up coverage of Nexus AG in November 2010, the share price stood at € 3.90, the company was barely known to investors, and was owned by management and a handful of investors. The company had just developed what would become the leading integrated technological platform for hospital software, enabling hospitals to improve their administrative, clinical, and diagnostic processes.
After hundreds of research updates and thousands of investor meetings over the course of countless roadshows in conjunction with CEO Ingo Behrendt, we were able to increase the free float from 50% to 90%. Through several placements and capital increases in 2012 and 2015 at € 10 and € 12, respectively, we were able to make renowned investors such as Fidelity, Invesco, Henderson, and Allianz long-term anchor investors for Nexus. It was a win-win situation for all parties concerned - Nexus was able to use the capital to finance organic growth and value-accretive acquisitions, was able to nearly triple their revenues since 2010, and the market capitalization increased sevenfold which pleased our investors greatly.